Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA)  is a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. The company is majorly involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Why should Investors make an EXIT?

• Increse in operating Expenses : For the quarter ending September 2021,the operating expenses increased from $6.85 million to $8.52 million, and the trend isn’t much expected to be changed as the company failed to make any announcement progressing towards expecting the sources of income lined for the the quarter ended December 2021.
• Weak technicals : The chart for the Hepion Pharmaceuticals, Inc., is on a weaker side and not showing any signs of revial in coming time any soon. The Relative Strength Index is pointing at 35.15, which is on the lower side and any further downside can take the price towards the south.
• Detiorating Financials: The quarter on quarter financials were not very impressive where the Net Losses increased from $7.67 million for the quarter ending June 2021 to the net loss of $9.27 million for September 2021 ending quarter.
• Macro headwinds : The recent talks echoing around the arena of rising interest rates sooner to counter the inflation, will put pressure on the company to raise short term funding for working capital, unless the organic cash generated from normal business operations. This is a headwind which the company is facing in near term, making it less attractive for the investors.

HEPA Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

HEPA's stock price has declined 59.13% in the past twelve months and is currently leaning towards the lower band of its 52-week range of USD 0.862 to USD 3.18. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 34.15.

Considering the correction in the stock price in the past twelve months, the detrirating financials and macro headwinds, regulatory approval, and associated risks, we recommend to ‘Sell’ the stock at the current price of USD 0.999 as of January 25, 2021, 03:25 PM ET.

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

* Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.